Premium
The use of brexpiprazole amongst individuals with insufficient outcomes with aripiprazole or bupropion: A case series
Author(s) -
Aladeen Traci,
Westphal Erica,
Lee Yena,
Rong Carola,
Rainka Michelle,
Capote Horacio,
McIntyre Roger S.
Publication year - 2018
Publication title -
perspectives in psychiatric care
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.538
H-Index - 35
eISSN - 1744-6163
pISSN - 0031-5990
DOI - 10.1111/ppc.12258
Subject(s) - tolerability , aripiprazole , bupropion , medicine , randomized controlled trial , psychiatry , psychology , adverse effect , schizophrenia (object oriented programming) , smoking cessation , pathology
Purpose We sought to characterize the clinical experience of outpatients treated with brexpiprazole after achieving suboptimal outcomes with aripiprazole or bupropion as determined by the treating psychiatric provider. Design and methods Case series; inefficacy, intolerability, or other unsatisfactory outcome to previous trial with aripiprazole or bupropion. Findings The majority of individuals in our sample exhibited tolerability of brexpiprazole. In addition, reduction in mean PHQ‐9 scores was observed with brexpiprazole treatment. Implications The results of our preliminary analysis suggest that a subpopulation of adults who have insufficient outcomes on aripiprazole or bupropion due to intolerability, inefficacy or other unsatisfactory outcome may benefit by switching to brexpiprazole treatment. Larger randomized controlled trials are needed, as well as sophisticated network analysis to further understand efficacy and tolerability differences between atypical antipsychotics.